Invega ER Starting Dose
The recommended starting dose of Invega ER (paliperidone extended-release) for adults is 6 mg once daily, taken in the morning without initial dose titration. 1
Standard Dosing for Adults
- Starting dose: 6 mg once daily (oral extended-release tablets)
- Dose range: 3-12 mg/day
- Maximum dose: 12 mg/day
- No titration required: Unlike many antipsychotics, paliperidone ER can be initiated at the therapeutic dose without gradual titration 2
The 6 mg starting dose represents the recommended therapeutic dose for most adults and is supported by the FDA-approved labeling 1. Peak plasma concentrations occur approximately 24 hours after dosing, with a terminal half-life of about 23 hours 2.
Dose Adjustments for Specific Populations
Antipsychotic-Naïve Patients
For patients who have never taken paliperidone or risperidone, establish tolerability with oral paliperidone or oral risperidone before initiating Invega ER. 1
- Lower starting doses (3 mg/day) should be considered for:
- Recently diagnosed patients
- Those with no prior antipsychotic exposure
- Patients with previous tolerability issues with other antipsychotics 3
Switching from Low-Potency Antipsychotics
When switching from antipsychotics with sedative and/or significant anticholinergic activity:
- Taper the pre-switch antipsychotic gradually while initiating paliperidone ER
- Consider temporary concomitant sedative medication during the transition to manage withdrawal symptoms 3
- Start with 6 mg/day unless tolerability concerns warrant 3 mg/day
When switching from antipsychotics with less sedating and minimal anticholinergic activity, the pre-switch medication can be tapered over a shorter period 3.
Renal Impairment
Renal function is critical for paliperidone dosing because renal excretion is the major route of elimination. 2
Dose adjustments based on creatinine clearance (CrCl):
- Mild renal impairment (CrCl 50-79 mL/min): Start with 3 mg once daily; maximum 6 mg/day
- Moderate to severe renal impairment (CrCl 10-49 mL/min): Start with 1.5 mg once daily; maximum 3 mg/day
- Severe renal impairment (CrCl <10 mL/min): Not recommended
The concentration-to-dose (C/D) ratio for oral paliperidone is approximately 4.1 ng/mL per mg/day and can be significantly influenced by renal impairment 4. Patients with severe renal impairment experience approximately two-fold higher drug exposure, necessitating substantial dose reductions 5, 6.
Elderly Patients
For elderly patients (≥65 years), start with 3 mg once daily and titrate cautiously based on tolerability. 7
- The presence of age-related decline in renal function is common and requires dose adjustment
- Elderly patients often have concomitant medical conditions that affect drug metabolism
- In clinical trials, paliperidone ER 3-12 mg/day was generally well-tolerated in elderly patients over 30 weeks 7
- Monitor for orthostatic hypotension, sedation, and extrapyramidal symptoms more closely in this population
Clinical Considerations
Higher Doses
Higher doses (9-12 mg/day) may be required for:
- Insufficient efficacy of previous antipsychotic
- Patients with acute symptoms
- When switching from risperidone (higher paliperidone doses may be needed compared to the risperidone dose) 3, 2
Monitoring Requirements
- Assess renal function before initiating treatment and periodically thereafter, especially in elderly patients 6, 8
- The lack of recognition of pre-existing renal impairment remains a significant clinical challenge 6
- Therapeutic drug monitoring (TDM) may be particularly valuable in patients with renal dysfunction to prevent drug accumulation and toxicity 4, 5
Common Pitfalls to Avoid
- Do not assume normal renal function in elderly patients without calculating creatinine clearance
- Do not use the same dose when switching from risperidone without considering that paliperidone may require higher doses for equivalent effect 3
- Do not overlook the 24-hour pharmacokinetic profile—once-daily dosing in the morning optimizes adherence and matches the drug's release characteristics 2